Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2023-01-24 00:00:00 ET · period of report 2023-01-20 · accession 0001567619-23-001209 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-24 | 2023-01-20 | CHRS | Vexler Vladimir | CSO | A - Grant | $0.00 | +40.0K | 131.3K | +44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-20 | A | A | 40,000 | $0.00 | 131,323 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 20 of each year, with the first 1/3 vesting on January 20, 2024 and with the RSUs being fully vested on January 20, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |